Key facts
- MedGenome Labs’s last known valuation is $603.0M (Jul 2025).
- It has raised $222.9M; the latest was Later Stage VC ($47.5M) in Jul 2025.
- Notable investors include Peak XV Partners, International Finance (Washington D.C.), Novo Holdings, ATEL Capital Group, Sofina — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for MedGenome Labs
- ·The full record, as it builds
Funding rounds
No funding rounds for MedGenome Labs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MedGenome Labs
Developer of sequencing genomics-based diagnostics and research platform intended for patients, pharmaceutical companies, and research institutions around the world. The company's platform applies genomics technologies, bioinformatics, computing and big data analytics to the genetically diverse and large population to understand the genetic basis of cancer, metabolic disorders, eye disorders and other rare diseases, and offers high-end genetic diagnostic tests across various disease categories; immuno-oncology, infectious diseases, reproductive health and rare diseases, enabling the healthcare industry to develop deep insights into diseases at the genetic and molecular level.
- Sector
- Healthcare
- HQ
- Bangalore, India
- Founded
- 2013
- Employees
- 1,000
- Website
- diagnostics.medgenome.com/
- Ownership
- Privately Held (backing)
MedGenome Labs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MedGenome Labs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MedGenome Labs in its N-PORT filings yet. We sweep new filings monthly.